Originally published May 22.

Genentech is planning to study whether the investigational drug crenezumab can prevent Alzheimer's in a patient population genetically predisposed to get the degenerative disease.

Moreover, by investigating the drug in a genetically homogeneous group, Roche subsidiary Genentech is hoping to test the theory that amyloid beta molecules – the major component comprising plaque deposits in the brains of Alzheimer's patients – cause the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.